Search Results
Results found for "Randy Hall"
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Avoid the professional threat of falling behind your peers by accessing the same insights that are driving lessons, classified industry news, priority event alerts, job opportunities, and insider commentary—all Don’t Fall Behind—Access the Edge You Need 👉 Become a Premium Member Today ➤ Already a Premium Member
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
APEX2 biosensor utilizes a fluorogenic substrate called Amplex UltraRed (AUR).
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
One successful strategy is the so-called metabolic surgery whose beneficial effects are beyond dietary
- First in Human: Early-stage COVID therapies hold promise against omicron variant
Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants , including the delta and omicron mutations, Vir CEO George Scangos said on a Dec. 7 call with analysts
- A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under Hypoxia: New..
its high chemoresistance and the presence of a cell subpopulation that persists under hypoxic niches, called
- The Hidden Cost of Unclear Biotech Positioning
Investor calls take too long before reaching substance. conversation drifts in a different direction , depending on who is asking the questions 2️⃣ Investor calls In reality, they all point to the same underlying problem .
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
ACKR1) was discovered on erythrocytes as the Duffy blood group antigen ( Cutbush et al., 1950 ), also called
- Intermolecular Interactions in G Protein-Coupled Receptor Allosteric Sites at the Membrane Interface
Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations "Allosteric modulators are called raises many questions about the ligand interactions and stability, the binding site structure, and how all
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
important role in the modulation of cardiac neurohormonal stress because it is the source of almost all aldosterone, of all epinephrine, and of a significant amount of norepinephrine reaching the failing Particular emphasis is given to findings from the past decade and a half that highlight the emerging β-arrestins in the adrenals, 2 protein families that regulate the signaling and functioning of GPCRs in all
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
Let’s build the systems now, before the next delay burns another half a million. 🚀 Book your free 30
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
Latest breakthroughs : Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition
- 📰 GPCR Weekly News
Advisory Board with appointment of immuno-oncology experts More millions roll in for Sosei Heptares Call
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
. 👉 Don’t Fall Behind—Access the Edge You Need 👉 Already a Premium Member?
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
the receptors the effects are different depending on which signaling pathway is activated, which is called
- 📢 GPCR Update: August 19-25, 2024 | Thrilling Announcement: New Pharmacology Course Dates & Exclusive Discounts Inside!
Innovation Forum Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 Call
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
New Tools for Getting Drugs Inside Cells All of this hinges on a simple question: can your compound get Persistent binding isn’t just about longer half-lives—it’s about smarter pharmacology.
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
All masterclasses — past and upcoming — are included with Premium Membership. On March 12, the University returns live with a half-day session focused on integrated GPCR discovery
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
drug discovery, one miscalculated liability can bring an otherwise promising scaffold to a complete halt mechanisms demand immediate attention, and how to build robust decision points into the cascade without falling Single-point thresholds for halting progression Cannot wholly exclude latent risks with a negative result Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
. 👉 What it looks like in real life: Meetings end with explanations, not decisions BD calls “went great
- How System-Level GPCR Thinking Prevents Discovery Failures
Don’t Fall Behind—Access the Edge You Need Already a Premium Member?
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Surgery electives meant long nights, constant patient responsibilities, and unpredictable call schedules
- Chemical signaling regulates axon regeneration via the GPCR-Gqα pathway in Caenorhabditis elegans
C. elegans secretes a family of small-molecule pheromones called ascarosides, which serve various functions
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
Part 5: Your Precision Blueprint : I'll tie it all together, providing a concise, actionable guide for scientific and operational guidance to accelerate discovery . 🚀 Book your free 30-minute strategy call
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Sharpen your discovery decisions ➤ GPCR Signal Transduction Call for Papers: Define What Comes Next Volume signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming. 👉 Access all
- Better GPCR Drug Discovery Decisions Start With Structured Learning
All courses remain included in Premium Membership. Access this week’s safety framework ➤ GPCRs: Signal Transduction — Volume II (Call for Papers, Deadline
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
In the late 20th century, nearly half of investigational drugs failed due to inadequate PK. The Four Fundamental Questions of PK All pharmacokinetic strategy reduces to four deceptively simple scaling assumptions and controls CYP inhibition, transporter assays, protein binding, and permeability all
- 📰 GPCR Weekly News - January 2 to 8, 2023
Sherwin Sells 30,000 Shares STALICLA signs agreement with Novartis on neurodevelopmental disorders Call
- 📰 GPCR Weekly News
Special report 2022: Meet 20 women blazing trails in biopharma R&D ERNEST - 2022 Scientific Outputs Call
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
." — DrGPCR University Attendee 🚀 Make better calls with better inputs.
- The Five Traps of Ignoring Kinetics
Kinetics in Drug Discovery: Your Edge If you’re still treating potency as a static number, you’re missing half




















